We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolome of Smokers Shows Early Signs of Damage

By LabMedica International staff writers
Posted on 17 Nov 2010
The blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage.

In a pilot study for evaluating the effect of cigarette smoking in humans, the global metabolomic profile was analyzed in the blood of individuals before and after smoking a cigarette. More...
The metabolites were traced in the context of relevant pathways that are affected by cigarette smoke including cell death, cell-cell interactions (a marker of inflammation), lipid metabolism, and gene expression.

In heavy smokers, metabolites were traced that were being produced after smoking back to damage in multiple organs and to a breakdown in the phospholipids that make up a cell's membrane, and a change in production of bile acids.

The scientists who carried out the study said that the findings illustrate the best analysis for chemicals unequivocally produced by smoking and indicate the potential toll that carcinogens and toxins poise to smokers years before lung cancer, heart disease, or other smoking-related diseases appear.

The study was presented by investigators from the Georgetown Lombardi Comprehensive Cancer Center, (Washington, DC, USA) part of Georgetown University Medical Center, at the Ninth AACR Frontiers in Cancer Prevention Research Meeting in Philadelphia (PA, USA), which was held from November 7-10, 2010.

Senior author of the study, Peter Shields, M.D., who specializes in tobacco carcinogenesis, said that new blood tests might be developed that will enable scientists to assess the harmfulness of one tobacco product compared to another. This would be useful to the federal U.S. Food and Drug Administration (FDA; silver Spring, MD, USA), the agency charged by Congress to begin controlling the contents of cigarettes.

Previously, cigarette manufacturers were only required to use machines that "smoked" cigarettes to derive the chemical content of potential carcinogens.

Related Links:

Georgetown Lombardi Comprehensive Cancer Center
US Food and Drug Administration



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.